NASDAQ · APLM
Healthcare · Biotechnology
$23.21
Down-$0.03 (-0.11%)
Updated Sep 14, 2026, 8:51 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
APLM closed at $23.21 after 19 trading sessions, down 1.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $24.03 | $24.03 | $21.21 | $23.205 | 5.85K |
| Sep 10, 2026 | $23.90 | $24.30 | $23.75 | $23.86 | 3.82K |
| Sep 9, 2026 | $24.48 | $26.2659 | $23.965 | $24.88 | 15.94K |
| Sep 8, 2026 | $26.64 | $27.3699 | $22.80 | $24.50 | 65.87K |
| Sep 4, 2026 | $27.495 | $27.495 | $27.495 | $27.495 | 1.52K |
| Sep 3, 2026 | $27.50 | $28.29 | $27.50 | $28.01 | 5.37K |
| Sep 2, 2026 | $26.73 | $28.00 | $26.30 | $27.3462 | 11.66K |
| Sep 1, 2026 | $27.09 | $27.09 | $26.04 | $26.94 | 6.65K |
| Aug 31, 2026 | $26.43 | $27.09 | $26.43 | $27.09 | 3.21K |
| Aug 28, 2026 | $27.40 | $27.497 | $26.45 | $26.60 | 6.34K |
| Aug 27, 2026 | $24.84 | $26.30 | $24.84 | $26.30 | 1.64K |
| Aug 26, 2026 | $24.901 | $27.505 | $24.901 | $26.20 | 4.23K |
| Aug 25, 2026 | $24.93 | $26.95 | $23.1392 | $26.50 | 10.55K |
| Aug 24, 2026 | $24.9999 | $24.9999 | $22.8001 | $23.1068 | 1.15K |
| Aug 21, 2026 | $22.93 | $24.59 | $22.93 | $24.3268 | 6.29K |
| Aug 20, 2026 | $24.27 | $24.4348 | $22.79 | $23.57 | 5.6K |
| Aug 19, 2026 | $23.92 | $24.00 | $21.00 | $23.59 | 7.94K |
| Aug 18, 2026 | $25.41 | $27.16 | $23.60 | $23.92 | 18.29K |
| Aug 17, 2026 | $22.96 | $25.50 | $22.3305 | $23.55 | 35.55K |
The latest Smart Investors Daily articles mentioning APLM.
APLM research
Company profile and research snapshot.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2024 | EF Hutton | Buy | — |
| Apr 1, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2023 | HC Wainwright & Co. | Buy | — |
| Oct 3, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 13, 2026
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and
Benzinga · Jun 24, 2026
Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and
Benzinga · Jun 18, 2026
globenewswire.com · Nov 19, 2025
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APLM.
No results
No recent SID articles mention APLM.
